ESMO World Congress on Gastrointestinal Cancer 2016

Oncology Meeting Resources

29 Jun - 02 Jul 2016, Barcelona, Spain

World GI 2016 Square Image

The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts from the ESMO World GI 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.





Format available

http://oncologypro.esmo.org/Meeting-Resourc...ts-with-locally-advanced-lower-rectal-cancer

Preoperative chemoradiotherapy with total mesorectal excision (TME) is the recommended standard therapy for patients with locally advanced rectal cancer. Sauer et al (N Engl J Med 2004) reported a...

Date: 29 Jun 2016
Presenter: C. Kosugi
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...with-locally-advanced-pancreatic-cancer-LAPC

Efficacious systemic therapies for LAPC may be associated with improved local disease control and overall survival (OS). The phase 3 MPACT trial in patients with previously untreated metastatic PC demonstrated longer OS (median, 8.

Date: 29 Jun 2016
Presenter: Hammel Pascal
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...olorectal-cancer-a-multicenter-phase-2-study

Hepatic resection is one of the treatment strategies for resectable liver metastases from colorectal cancer. The role of neoadjuvant and adjuvant chemotherapy in the management of initially resectable...

Date: 29 Jun 2016
Presenter: Satake Hironaga
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...lorectal-carcinoma-phase-2-KEYNOTE-164-study

Approximately 5% of metastatic colorectal carcinomas (CRCs) are mismatch-repair (MMR) deficient, leading to high levels of microsatellite instability (MSI). CRCs with high MSI (MSI-H) contain abundant...

Date: 29 Jun 2016
Presenter: Le Dung
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...rcinoma-randomized-phase-3-KEYNOTE-177-study

Approximately 5% of metastatic colorectal carcinomas (CRCs) are mismatch-repair (MMR) deficient, leading to high levels of microsatellite instability (MSI). CRCs with high MSI (MSI-H) contain abundant...

Date: 29 Jun 2016
Presenter: Diaz Luis
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...-Naive-Metastatic-Colorectal-Cancer-SAPPHIRE

In Japan, oxaliplatin/5-FU/leucovorin (mFOLFOX6) is the most frequent first-line chemotherapy backbone for metastatic colorectal cancer (mCRC). However, peripheral nerve disorders caused by oxaliplatin ...

Date: 29 Jun 2016
Presenter: N. Nagata
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...-mCRC-in-routine-clinical-practice-CORRELATE

Two randomized, double-blind, phase 3 trials have shown that the oral multikinase inhibitor regorafenib significantly improves overall survival vs placebo in patients with mCRC that has progressed on...

Date: 29 Jun 2016
Presenter: Ducreux Michel
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...ancer-and-pancreatic-adenocarcinoma-patients

A selective anti-PD-1 antibody, nivolumab (N), blocks the interaction between programmed death-1 (PD-1) on T-cells and PD-L1 and PD-L2 on tumor cells. We report safety and clinical activity of N combined...

Date: 29 Jun 2016
Presenter: V. Khemka
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...ow-up-of-retroperitoneal-soft-tissue-sarcoma

Treatment and survival features in a consecutive series of 89 patients affected by primary or recurrent retroperitoneal sarcoma (RPS) were reported. Eighty-three among them underwent resection and all...

Date: 29 Jun 2016
Presenter: A. Chiappa
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...he-rectum-with-germination-in-genital-organs

Given the fact that in 55-60% of cases, colorectal cancer is diagnosed in stages 3-4 of the disease, there is a trend to increase the number of patients with spread to the organs of the genitals in women.

Date: 29 Jun 2016
Presenter: A. Abdujapparov
Resources: Abstract